Autonomize AI Secures $4 Million to Help Healthcare and Life Sciences Companies Drive Down Costs with Trusted AI

• Traction gained in clinical trials enables Autonomize AI to launch new generative-AI and clinical large-language-model-based solutions to improve patient outcomes

• Autonomize AI products organize, contextualize and summarize unstructured data so non-technical knowledge workers can make data-driven decisions

• Customers using Autonomize AI solutions have realized significant ROI within months

Autonomize AI, the trusted artificial intelligence (AI) company for healthcare and life sciences, announced it has closed a $4 million seed round to support the development and scaling of the company’s AI platform. Asset Management Ventures led the round, with participation from ATX Venture Partners, Loop Ventures and The Next Practices Group.

 Latest AiThority Interview Insights : AiThority Interview with Brad Anderson, President of Product and Engineering at Qualtrics

“We are putting the patient back in the center of the healthcare ecosystem by empowering every knowledge worker with insights, content and context to do their best work and drive 100-times better patient outcomes. We are assembling some of the best scientists, researchers and engineers to solve this critical problem.”

“Despite the abundance of data and the availability of cutting-edge technology like AI, healthcare is broken for the patient,” said Ganesh Padmanabhan, Autonomize AI founder and CEO. “We are putting the patient back in the center of the healthcare ecosystem by empowering every knowledge worker with insights, content and context to do their best work and drive 100-times better patient outcomes. We are assembling some of the best scientists, researchers and engineers to solve this critical problem.”

Autonomize AI will use the seed funding to boost its R&D and commercialization efforts. Launched in 2022, Autonomize AI provides software products to lower costs and improve operational efficiencies for healthcare and life sciences organizations. Its products include:

• Autonomize Pixel, which accelerates clinical trials through more efficient workflows and optimal protocol design, feasibility studies and patient matching.
• Autonomize Wizard, which augments clinical decisions by providing multi-modal chart insights for research, payer administration, registries and decision-making.
• Generative AI, which offers conversational, search and summarization capabilities for secure internal data sources, contextualized for different user types.

“We believe that Autonomize AI holds the key to unlocking the vast potential of artificial intelligence in revolutionizing healthcare,” said Skip Fleshman, Asset Management Ventures General Partner. “While there is a lot of talk about AI in healthcare, extracting the insights buried within unstructured medical data in various silos is essential for fostering breakthroughs in patient care and overall health outcomes. We are thrilled to partner with this seasoned team, as they lead the charge in harnessing the power of AI to create a healthier future for all.”

Autonomize AI’s solutions are built on a secure cloud-based platform optimized for the healthcare industry that supports multi-modal data types and uses pre-trained medical large language models (LLMs). These LLMs may be fine-tuned to private data and deployed into virtual private cloud environments. Autonomize AI’s privacy filter automatically identifies and anonymizes personally identifiable information and personal health information. The company’s platform ensures organizations can use AI capabilities without compromising patient-data privacy and security. By focusing on human-centered workflows, Autonomize AI is building the equivalent of the J.A.R.V.I.S. system (featured in Marvel’s Iron Man movies) for all healthcare workers to augment and empower their expertise.

Read More about AiThority Interview: AiThority Interview with Ahmad Al Khatib, CEO and Founder at Qudo

Cutting costs, eliminating inefficiencies

Human administrative overhead is responsible for about $765 billion annually in unnecessary costs. Additionally, drug launches take 10 to 15 years and cost more than $2 billion due to inefficiencies in recruiting and retaining patients during clinical trials.

The problem? Ninety percent of the data relied upon for clinical decisioning is unstructured and impossible to analyze at scale. As a result, most processes remain manual and inefficient. Organizing that data so it is instead structured and contextually linked is critical to assist often non-technical knowledge workers make decisions based on data. Padmanabhan founded Autonomize AI precisely to surmount this challenge.

“We evaluated several vendors building vertical solutions for patient matching and medical records review, but they offered limited solutions,” said Ivor Clarke, SubjectWell Chief Operating Officer. “Almost no existing platform consumes unstructured data and serves multiple contextual use cases. Autonomize AI has added tremendous value to SubjectWell in a short period of time by making our medical records review for clinical trials 10 times more efficient and accurate.”

Autonomize AI’s products can be integrated into existing workflows through APIs. Current customers already have realized a strong return on investment within months.

AiThority Interview Insights: AiThority Interview with Vova Kyrychenko, CTO at Xenoss

 [To share your insights with us, please write to sghosh@martechseries.com]